ArticlePloS one2016
Ketamine Metabolites Enantioselectively Decrease Intracellular D-Serine Concentrations in PC-12 Cells.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 23 citations in OpenAlex.
- d-Serine is a potential biomarker for clinical response in treatment of post-traumatic stress disorder using (R,S)-ketamine infusion and TIMBER psychotherapy: A pilot study.Biochimica et biophysica acta. Proteins and proteomics · 2018Trial
- Ketamine and Major Ketamine Metabolites Function as Allosteric Modulators of Opioid Receptors.Molecular pharmacology · 2024Article
- Mechanisms of ketamine and its metabolites as antidepressants.Biochemical pharmacology · 2022Review
- Gut Microbial Dysbiosis and Cognitive Impairment in Bipolar Disorder: Current Evidence.Frontiers in pharmacology · 2022Review
- Hydroxynorketamines: Pharmacology and Potential Therapeutic Applications.Pharmacological reviews · 2021Review
- Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers.Therapeutic advances in psychopharmacology · 2020Article
- Molecular Pharmacology and Neurobiology of Rapid-Acting Antidepressants.Annual review of pharmacology and toxicology · 2019Review
- Mouse, rat, and dog bioavailability and mouse oral antidepressant efficacy of (Journal of psychopharmacology (Oxford, England) · 2019Article
- Molecular basis of atypicality of bupropion inferred from its receptor engagement in nervous system tissues.Psychopharmacology · 2018Article
- Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms.Pharmacological reviews · 2018Review
- Stereochemical and structural effects of (2R,6R)-hydroxynorketamine on the mitochondrial metabolome in PC-12 cells.Biochimica et biophysica acta. General subjects · 2018Article
- Alterations in amino acid levels in mouse brain regions after adjunctive treatment of brexpiprazole with fluoxetine: comparison with (R)-ketamine.Psychopharmacology · 2017Article
- Subchronic administration of (R,S)-ketamine induces ketamine ring hydroxylation in Wistar rats.Journal of pharmaceutical and biomedical analysis · 2016Article
- Hydroxynorketamine: Implications for the NMDA Receptor Hypothesis of Ketamine's Antidepressant Action.Chronic stress (Thousand Oaks, Calif.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
D-Serine is an endogenous NMDA receptor co-agonist that activates synaptic NMDA receptors modulating neuronal networks in the cerebral cortex and plays a key role in long-term potentiation of synaptic transmission. D-serine is associated with NMDA receptor neurotoxicity and neurodegeneration and elevated D-serine concentrations have been associated with Alzheimer's and Parkinsons' diseases and amyotrophic lateral sclerosis. Previous studies have demonstrated that the ketamine metabolites (rac)-dehydronorketamine and (2S,6S)-hydroxynorketamine decrease intracellular D-serine concentrations in a concentration dependent manner in PC-12 cells. In the current study, PC-12 cells were incubated with a series of ketamine metabolites and the IC50 values associated with attenuated intracellular D-serine concentrations were determined. The results demonstrate that structural and stereochemical features of the studied compounds contribute to the magnitude of the inhibitory effect with (2S,6S)-hydroxynorketamine and (2R,6R)-hydroxynorketamine displaying the most potent inhibition with IC50 values of 0.18 ± 0.04 nM and 0.68 ± 0.09 nM. The data was utilized to construct a preliminary 3D-QSAR/pharmacophore model for use in the design of new and more efficient modulators of D-serine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.